Sanofi India Ltd

Sanofi India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. The stock’s recent performance, coupled with mixed signals from MACD, RSI, and moving averages, suggests increasing caution for investors amid a challenging market backdrop.

Sanofi India Ltd has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. While the stock’s weekly indicators suggest a mild recovery, monthly trends remain subdued, underscoring the challenges facing this Pharmaceuticals & Biotechnology player amid broader market volatility.

Sanofi India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a recent upgrade in its Mojo Grade from Sell to Hold, the stock faces mounting pressure from moving averages and monthly technicals, reflecting challenges in sustaining upward price momentum.

Sanofi India Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced shift in its overall outlook. This change is driven by a combination of factors including improved quality metrics, attractive valuation, stable financial trends, and mixed technical signals. Despite some challenges in long-term growth, the company’s strong management efficiency and favourable dividend yield have contributed to this reassessment.

Sanofi India Ltd’s shares declined to a fresh 52-week low of Rs.3976.4 on 21 Jan 2026, marking a continuation of the stock’s downward trajectory over recent sessions and reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Sanofi India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Sanofi India Ltd’s stock price declined to a fresh 52-week low of Rs.4025 on 14 Jan 2026, marking a significant milestone in its ongoing downward trajectory. The pharmaceutical company’s shares have underperformed both the sector and broader market indices, reflecting persistent challenges in growth and valuation metrics.

Sanofi India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 August 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 09 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Sanofi India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 12 August 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 29 December 2025, providing investors with an up-to-date view of the company's performance and outlook.

Sanofi India’s share price reached a new 52-week low of Rs.4050 today, reflecting a continued downward trend over the past year. The stock’s performance contrasts with broader market movements, as it underperformed its sector and key indices amid subdued sales growth and profit metrics.

Sanofi India’s share price reached a fresh 52-week low of Rs.4064.8 today, marking a continuation of its downward trajectory over the past eight trading sessions. The stock has recorded a cumulative return of -6.43% during this period, underperforming its Pharmaceuticals & Biotechnology sector peers and broader market indices.

Sanofi India has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters amid a backdrop of subdued financial results and persistent stock underperformance within the Pharmaceuticals & Biotechnology sector.

Sanofi India’s share price reached a fresh 52-week low of Rs.4095.3 today, marking a significant milestone in a sustained period of decline. The stock has been on a downward trajectory for the past seven consecutive sessions, reflecting a cumulative return of -5.69% over this period, signalling ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Sanofi India’s shares reached a fresh 52-week low of Rs.4142.95 today, marking a continuation of a downward trend that has seen the stock underperform both its sector and broader market indices over the past year.

Sanofi India’s shares have reached a 52-week low, closing near Rs 4,145.9, marking a significant price level after a sustained period of decline. The stock’s recent performance reflects ongoing pressures within the Pharmaceuticals & Biotechnology sector, with the share price now trading below all key moving averages.

Sanofi India has experienced a revision in its evaluation metrics reflecting a shift in market assessment, influenced by recent financial trends and technical indicators. The pharmaceutical company’s performance data and sector context provide insight into the factors shaping this change.

Sanofi India has reached a 52-week low, reflecting a challenging period with a significant decline over the past year. The stock is trading below key moving averages, although it maintains a high dividend yield and strong management efficiency. Long-term growth prospects appear subdued amid negative sales and profit trends.